Followers | 145 |
Posts | 27547 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Friday, September 15, 2017 9:23:30 AM
Ltd.’s FY2021 Earnings (BLRX)
https://www.dispatchtribunal.com/2017/09/13/brokers-set-expectations-for-biolinerx-ltd-s-fy2021-earnings-blrx.html
BioLineRx Ltd. (NASDAQ:BLRX) – Stock analysts at Oppenheimer Holdings issued their FY2021 earnings per share (EPS) estimates for BioLineRx in a research report issued on Tuesday. Oppenheimer Holdings analyst M. Breidenbach forecasts that the biotechnology company will earn $0.06 per share for the year. Oppenheimer Holdings has a “Buy” rating and a $3.00 price objective on the stock.
Get BioLineRx Ltd. alerts:
Enter Your Email Address
Submit
Other analysts also recently issued reports about the stock. HC Wainwright set a $4.00 target price on shares of BioLineRx and gave the company a “buy” rating in a research note on Saturday,
Recent BLRX News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/04/2024 12:47:21 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/28/2024 12:08:12 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/16/2024 12:07:06 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/08/2024 05:15:22 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/29/2023 09:20:42 PM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 12/29/2023 09:15:45 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/21/2023 12:05:53 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/12/2023 12:07:30 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/20/2023 12:03:18 PM
- Monday’s Wall Street Highlights: GM, Microsoft, Citigroup, Amazon, and more • IH Market News • 11/20/2023 11:25:08 AM
- BioLineRx a conclu un accord de licence exclusive pour le motixafortide en Asie, sous les conseils de MSQ Ventures • PR Newswire (Canada) • 11/01/2023 11:43:00 AM
- BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures • PR Newswire (Canada) • 10/31/2023 01:00:00 PM
- BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures • PR Newswire (US) • 10/31/2023 01:00:00 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 10/26/2023 06:18:00 PM
- New Collaboration Could Revolutionize Treatment of Chronic Spinal Cord Injuries • AllPennyStocks.com • 10/18/2023 09:07:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/12/2023 11:14:17 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/28/2023 11:11:10 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/11/2023 11:07:26 AM
- BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma • PR Newswire (US) • 09/11/2023 11:00:00 AM
- Wednesday’s Wall Street Highlights: Ambarella, Alphabet, Toyota, HP Inc, Vinfast, and more • IH Market News • 08/30/2023 11:16:41 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/30/2023 11:15:24 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/30/2023 10:45:19 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/08/2023 09:25:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/17/2023 11:10:43 AM
UC Asset Expected to Report $0.03/share Net Profit for 2023 • UCASU • Apr 11, 2024 10:00 AM
Kona Gold Beverages & Apple Rush Co. Execute Joint Venture & Manufacturing Agreement • APRU • Apr 11, 2024 9:40 AM
VAYK Confirmed Its Eligibility for $1.8 Million Investment through Federal EB5 Program • VAYK • Apr 11, 2024 9:00 AM
ILUS Moves Forward With Its Two Subsidiary Uplists and Equity Dividend • ILUS • Apr 10, 2024 9:36 AM
Quartz Intersects 102m of 2.22 g/t Au and 104 g/t Ag Announces New Discovery at Prodigy on its Maestro Project, British Columbia • QZM • Apr 10, 2024 8:00 AM
Swifty Global Announces Record Annual Results Ahead of National Exchange Reverse Merger • DRCR • Apr 9, 2024 1:55 PM